How did Julie Gerberding go from CDC director to Merck's vaccine division?

Julie Gerberding served as CDC Director from 2002 to 2009, overseeing recommendations related to Merck's Gardasil vaccine and studies related to Merck's MMR vaccine. In 2010 — just one year after leaving the CDC — she joined Merck as President of Vaccines. She ultimately cashed in over $22 million in Merck stock. Aaron Siri argues she "aggressively protected Merck's products, and hence Merck's profits" during her CDC tenure.

How much money did Julie Gerberding make from Merck stock?

Gerberding cashed in over $22 million in Merck stock after joining the company as President of Vaccines in 2010. She had previously served as CDC Director (2002-2009), where she oversaw vaccine policy decisions directly affecting Merck's most commercially important products including Gardasil and MMR.

What does the Gerberding case reveal about the FDA-pharma revolving door?

A secretly recorded Pfizer Director of Research and Development stated: "In the pharma industry, all the government officials who review our drugs eventually come work for pharma companies." When asked why, he explained: "Because if the regulators who review our drugs know that once they stop being a regulator they want to go work for the company, they are not going to be as harsh on the company where they're getting their job."

Did Julie Gerberding make vaccine decisions that benefited Merck while at CDC?

During her CDC tenure (2002-2009), Gerberding oversaw recommendations related to Merck's Gardasil HPV vaccine and studies related to Merck's MMR vaccine and autism. Aaron Siri argues this created a pattern where government employees who advance pharma's interests are subsequently rewarded with lucrative private-sector positions, incentivizing current officials to favor industry interests in anticipation of future employment.

Julie Gerberding — From CDC Director to Merck

Q: Is the revolving door between regulators and pharma companies common?

Yes. Siri presents Gerberding as the clearest documented example but argues it reflects a systemic pattern. The revolving door mechanism does not require corruption or conspiracy — government officials simply know that favorable treatment of pharma products improves their post-government career prospects. Siri argues this is one of several mechanisms of regulatory capture, alongside direct financial conflicts, career incentives, and industry user fee dependence.

Julie Gerberding served as CDC director from 2002 to 2009, then became president of Merck's $5 billion vaccine division — the most prominent example of the regulatory-to-industry revolving door in vaccine policy.

Dr. Julie Gerberding served as Director of the CDC from 2002 to 2009, overseeing vaccine policy during a critical period. According to Siri, her subsequent career trajectory — joining Merck as president of vaccines in 2010 and earning over $22 million in Merck stock — is the clearest documented example of the pharma "revolving door" in vaccine policy.

Background

Role in Vaccine Policy

Siri cites Gerberding as a case study in how pharma uses government positions as a feeder for industry roles, and vice versa. The pattern he describes:

3. This creates an incentive for current government employees to favor industry interests, anticipating future employment opportunities

Gerberding "aggressively protected Merck's products, and hence Merck's profits" during her CDC tenure, according to Siri — then joined Merck the year after leaving the CDC. She cashed in over $22 million in Merck stock in this role.

The Revolving Door: Industry Confirmation

Siri also cites a 2023 secretly recorded statement by a Pfizer Director of Research and Development (captured by a Project Veritas journalist):

> "In the pharma industry, all the government officials who, like you know, review our drugs, eventually come work for pharma companies."

When asked how he felt about the revolving door: "It's pretty good for the industry to be honest. It's bad for everyone else in America."

When asked why: "Because if the regulators who review our drugs, you know that once they stop being a regulator they want to go work for the company, they are not going to be as harsh on the company where they're getting their job."

Conflicts of Interest / Affiliations

Criticism and Controversy

Siri presents Gerberding as emblematic of regulatory capture through career incentives — a mechanism that, he argues, does not require corruption or conspiracy. Government officials simply know that favorable treatment of pharma products improves their post-government career prospects. Gerberding was responsible for vaccine-related decisions at the CDC affecting Merck's most commercially important products, then joined Merck directly.

Period	Role	Entity
2002–2009	CDC Director	Federal government (US)
2010+	President of Vaccines	Merck
Undisclosed	Merck stock holdings	Merck ($22M+ cashed in)